Cargando…
T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris
Autores principales: | Croitoru, David O., Piguet, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030000/ https://www.ncbi.nlm.nih.gov/pubmed/36959025 http://dx.doi.org/10.1016/j.jid.2023.02.002 |
Ejemplares similares
-
SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris
por: Fenizia, Claudio, et al.
Publicado: (2023) -
Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012) -
Refractory pemphigus vulgaris treated with rituximab and mycophenolate
mofetil
por: Biot, Stephanie Del Rio Navarrete, et al.
Publicado: (2014) -
Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
por: Benesh, Gabrielle, et al.
Publicado: (2021) -
AZD-1222/rituximab: Pemphigus vulgaris and pemphigus vulgaris flare-up: 2 case reports
Publicado: (2022)